Quoin Pharmaceuticals (NASDAQ:QNRX) announced that the European Medicines Agency has granted orphan drug designation to QRX003 for the treatment of Peeling Skin Syndrome, a rare genetic skin disorder.
Ocugen (NASDAQ:OCGN) entered an agreement granting Roots Pharmaceutical exclusive regional rights to OCU400, an investigational gene therapy for retinitis pigmentosa, an inherited vision-loss disease.
BlackRock (NYSE:BLK) reported third-quarter 2026 financial results with revenue of $7.8 billion, representing a 19% increase compared with the same period last year.
Verastem Oncology (NASDAQ:VSTM) reported updated Phase 1/2 TARGET-D 101 trial results for VS-7375, an investigational oral KRAS G12D inhibitor, across multiple KRAS G12D-mutated solid tumors.
Yiren Digital (NYSE:YRD) reaffirmed its intention to continue implementing its previously announced share repurchase program of up to US$20 million.
High Templar Tech (NYSE:HTT) reported first-half 2026 shareholder net income of RMB416.9 million, compared with RMB461.9 million in the same period last year.
Oil prices moved higher after vessels were struck in the Strait of Hormuz and Iranian officials said new tactics were being used to target ships in the region.
Rhythm Pharmaceuticals (NASDAQ:RYTM) commercially launched IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity following its inclusion on the national insurance price list.
Alvotech (NASDAQ:ALVO) and Advanz Pharma submitted a regulatory application in Europe for AVT29, a proposed biosimilar referencing Eylea 8 mg, a treatment used for retinal diseases.
ASML (NASDAQ:ASML) reported third-quarter 2026 results with net sales of €11.7 billion, compared with higher profitability in the previous quarter due to improved gross margin and net income.
In an interview on October 14, 2026, Anthropic's Head of International Startups & Digital Native, Guillaume Princen, discussed how startups and major firms are adopting Anthropic's AI, including Claude tools, to boost employee productivity, overhaul processes, and build new products. He highlighted growing demand for frontier models like Opus 5.5, now about 40% cheaper than its predecessor, and a shift toward using different models for specific tasks across the 5.5 family. Princen emphasized Anthropic's safety-first approach versus open-source and open-weight competitors, underscoring third-party auditing, closer cooperation with governments, and willingness to delay or limit powerful model releases such as with Methos if safety concerns arise, even at the expense of near-term revenue. Original filename: 20261014_080546_Interview_of_Guillaume_Princen_on_Anthropic_s_AI_Strategy.mp4
Danaher (NYSE:DHR) announced a collaboration with NVIDIA (NASDAQ:NVDA) to combine its scientific instruments and laboratory processes with artificial intelligence technologies.
